Tongjitang Pharmaceuticals (NYSE: TCM) announced its mainstay traditional Chinese medicine for osteoporosis, Xianling Gubao, was effective in a two-year trial. The randomized, double-blind, multi-center study demonstrated that Xianling Gubao prevented bone resorption and increased bone density. The trial was conducted in patients with post-menopausal osteoporosis. More details... (Additional information added on October 30)

Stock Symbol: (NYSE: TCM)